Therapeutic Phlebotomy Protocol for Erythrocytosis

Indications for Therapeutic Phlebotomy

The American Heart Association recommends therapeutic phlebotomy when hemoglobin exceeds 20 g/dL and hematocrit exceeds 65%, accompanied by symptoms of hyperviscosity such as headache, fatigue, or poor concentration, and in the absence of dehydration or anemia 1, 2, 3
Symptoms that warrant intervention include headache, increasing fatigue, and poor concentration, as indicated by the American College of Cardiology 2
Phlebotomy should not be performed in the presence of dehydration or anemia, according to the European Society of Cardiology 1, 2
Pre-operative phlebotomy may occasionally be indicated to improve coagulation before elective surgery, as suggested by the American College of Surgeons 2

The European Heart Journal recommends removing one unit of blood (approximately 400-500 mL) per session, and replacing it with an equal volume of isotonic saline or dextrose (750-1000 mL of isotonic saline) 2, 3
For patients with polycythemia vera, the Mayo Clinic recommends maintaining hematocrit below 45% in men and at appropriate corresponding values for women and other races 4
The Journal of Hepatology suggests targeting serum ferritin of 50 μg/L during the induction phase, but not lower to avoid iron deficiency 5, 6

The Journal of Hepatology recommends performing phlebotomy weekly or fortnightly until target levels are reached during the induction phase for patients with iron overload conditions like hemochromatosis 6
For maintenance phase in erythrocytosis, the frequency should be individualized based on the rate of red cell production, as indicated by the Journal of Hepatology 5

The American Heart Association warns that repeated routine phlebotomies are not recommended due to the risk of iron depletion, decreased oxygen-carrying capacity, and stroke 1, 2, 7
Iron deficiency, even with erythrocytosis, is undesirable as it reduces oxygen-carrying capacity, decreases red blood cell deformability, and increases stroke risk, according to the American College of Cardiology 2
The European Society of Cardiology recommends monitoring for signs of iron deficiency through peripheral blood smear and serum ferritin or transferrin saturation 2

For pregnant women with mild to moderate iron overload without advanced liver disease, phlebotomy can be paused during pregnancy in most cases, as suggested by the Journal of Hepatology 6
In patients with congenital heart disease and cyanosis, judicious phlebotomy to a hematocrit level of 60% may be reasonable to alleviate hyperviscosity symptoms, according to the Mayo Clinic 8
For patients who cannot undergo phlebotomy, iron chelation therapy can be considered after careful risk-benefit assessment, as recommended by the Journal of Hepatology 5, 6

Regular monitoring of hemoglobin, hematocrit, and iron status is essential, as indicated by the American Heart Association 2
The European Society of Cardiology recommends assessing for symptoms of hyperviscosity before each phlebotomy session 1, 2
Monitoring for signs of iron deficiency, which may require adjustment of phlebotomy schedule, is crucial, according to the American College of Cardiology 2

Erythrocytapheresis can be considered in selected cases where phlebotomy is not feasible, allowing for fewer hemodynamic changes compared to phlebotomy and returning valuable blood components, according to the Journal of Hepatology guidelines 9
Iron chelation therapy, such as deferasirox, can be considered as a second-line option when phlebotomy is not possible, after careful risk-benefit assessment, as recommended by the Journal of Hepatology 9